University Hospitals Leicester
Welcome,         Profile    Billing    Logout  
 9 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fennell, Dean A
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed
2/3
176
Europe
MesoPher
Amphera BV, TMC Pharma
Mesothelioma
06/22
06/22
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
Bomalaski, John S
NCT05317819: Study of ADI-PEG 20 Versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma

Recruiting
3
300
RoW
ADI-PEG20, pegargiminase, Placebo
Polaris Group
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
09/25
10/25
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Recruiting
2
40
RoW
ADI-PEG20, Pegargiminase, Placebo
Polaris Group
Nonalcoholic Steatohepatitis (NASH)
12/27
01/28
POLARIS2020-002, NCT05001828: Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Recruiting
1
60
US
ADI-PEG 20, Venetoclax, Azacitidine
Polaris Group
Acute Myeloid Leukemia, Adult
07/25
12/25
Bown, Matt J
No trials found
Beeston, Emma P
No trials found
Fawke, Joe
No trials found
Matar, Maz
No trials found
Roopun, Rehanah
No trials found
Mughal, Kamaal
No trials found
Messeder, Sarah Jane
No trials found
Abraham, Niranjan
No trials found
Blochlinger, Georgina
No trials found

Download Options